Clinical trials: Metastatic
Aneurysmal Subarachnoid Haemorrhage
CytoSorb SAH Trial
In aSAH high levels of IL-6 (a pro-inflammatory cytokine) in the cerebrospinal fluid, as well as systemically have been linked to the severity grade and the occurrence of vasospasm and delayed cerebral ischemia caused by…
- Trial name
- NCT05259514
- Testing
- CytoSorb
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Emanuela Keller
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04647916
- Testing
- Sacituzumab Govitecan
- Where
- 296 sites in United States
- Volunteers
- 44 people
- Sponsor
- SWOG Cancer Research Network
Neuroendocrine Tumors, Neoplasm Metastasis
DEBOXA for Inoperable NET Liver Metastases
A prospective clinical trial to study the safety and effectiveness of Transcatheter Artery Chemotherapy and Embolization (TACE) using CalliSpheres Drug-Eluting Beads with oxaliplatin (DEBOXA) in treating patients who have…
- Conditions
- Neuroendocrine Tumors, Neoplasm Metastasis, Liver
- Trial name
- NCT03881306
- Testing
- D-TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiangya Hospital of Central South University
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients
The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
- Trial name
- RECAP (NCT01423604)
- Testing
- Capecitabine, Ruxolitinib
- Where
- 39 sites in United States
- Volunteers
- 136 people
- Sponsor
- Incyte Corporation
Recurrent Vulvar Cancer, Persistent Vulvar Cancer
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.
- Conditions
- Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer
- Trial name
- PIERCE (NCT05903833)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 15 sites in Germany
- Volunteers
- 42 people
- Sponsor
- AGO Research GmbH
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
This study is for patients with cancer of the prostate gland that has metastasized or spread outside the prostate to other parts of the body.
- Trial name
- NCT00327340
- Testing
- custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Achieve Life Sciences
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer
This is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis.
- Trial name
- NCT07512674
- Testing
- Receiving lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy and bevacizumab targeted therapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Esophageal Cancer
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma who failed Standard first line therapy.
- Trial name
- NCT05866510
- Testing
- Utidelone and anlotinib
- Where
- 3 sites in China
- Volunteers
- 47 people
- Sponsor
- Peking University
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable…
- Trial name
- B-FAST (NCT03178552)
- Testing
- Alectinib, Atezolizumab, Pemetrexed
- Where
- 161 sites in United States, Argentina and 25 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
Study SC-101 in Subjects With Advanced Malignancies
This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT06220838
- Testing
- SC-101
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
Primary Hypertension, Secondary Hypertension
Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension
This open label 4 month study will evaluate efficacy (blood pressure lowering effects) and safety of lisinopril in children 1-18y whose parents grant permission to participate.
- Trial name
- Lisi-ped (NCT02184858)
- Testing
- lisinopril, ACE-inhibitor
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- University Ghent
Gastric Cancer Stage IV, Peritoneal Carcinomatosis
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6
Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic chemotherapy.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel, mFOLFOX6
- Trial name
- IPLUS (NCT03618758)
- Testing
- Paclitaxel, mFOLFOX6 regimen
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Seoul National University Bundang Hospital
Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy
- Trial name
- NCT04996758
- Testing
- Toripalimab and Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Melanoma (Skin Cancer)
MELanoma Brain Metastasis Treated With CYberknife
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.
- Trial name
- MELCY (NCT07691255)
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Cancer
Lapatinib in Combination With Vinorelbine
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior…
- Trial name
- NCT01128543
- Testing
- lapatinib and Vinorelbine
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer Metastatic
Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients
This is a phase IV multicenter trial to evaluate real-world health outcomes and economic impact of panitumumab versus standard-of-care (SOC) in the treatment of patients with chemotherapy-refractory metastatic colorectal cancer…
- Trial name
- NCT02139215
- Where
- 5 sites in Canada
- Volunteers
- 72 people
- Sponsor
- PeriPharm
Non-Small Cell Lung Cancer
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
This 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients with locally advanced or metastatic non-small cell…
- Trial name
- NCT00718315
- Testing
- erlotinib [Tarceva], fusidic acid [Verutex], erythromycin [Eritex]
- Where
- 26 sites in Brazil
- Volunteers
- 201 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite…
- Trial name
- RELATIVITY-123 (NCT05328908)
- Testing
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Where
- 139 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies.
- Trial name
- MCW I-PREDICT (NCT05674825)
- Testing
- Targeted agent, Standard of care agent
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Medical College of Wisconsin
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.